OR WAIT null SECS
Catalent expands capabilities for stem cell-based therapies with acquisition of RheinCell’s GMP-grade human iPSCs.
Catalent announced on June 24, 2021 an agreement to acquire RheinCell Therapeutics GmbH, a Langenfeld, Germany-based developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs), further expanding its custom cell therapy process development and manufacturing capabilities.
In making the announcement, Catalent reported that the acquisition will allow it to offer the building blocks to scale iPSC-based cell therapies and reduce barriers to entry to the clinic for therapeutic companies.
iPSC cell types can address a number of therapeutic indications. RheinCell has researched and developed full GMP human leukocyte antigen-matched cell banks.
Upon closing, which is expected before the end of 2021, RheinCell’s current employees will join Catalent’s Cell & Gene Therapy business.